Drug intelligence / Profile preview

verapamil

Development stage
Approved
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Verapamil is a non-dihydropyridine calcium channel blocker used primarily to treat hypertension (high blood pressure), angina pectoris (chest pain), and certain cardiac arrhythmias, including supraventricular tachycardia and atrial fibrillation/flutter. It works by inhibiting the influx of calcium ions through slow channels in myocardial and vascular smooth muscle cells, leading to relaxation of blood vessels, reduced heart workload, increased oxygen supply to the heart, and slowed electrical conduction through the atrioventricular node. This results in lowered blood pressure, relief from angina symptoms, and control of abnormal heart rhythms. Off-label uses include prevention of cluster headaches and migraine prophylaxis[1][2][3][4][5].

Brand names
CalanCalan SRIsoptinIsoptin SRVerelanVerelan PMCovera-HSSecuronAkilenCordilox
Other names
IproveratrilDilacoranIsoptimoVerapamilo (INN-Spanish)Verapamilum (Latin)(+/-)-Verapamil hydrochlorid
02

Targets

HK1 (Hexokinase type I (mitochondrial))KCNH2 (Voltage-gated potassium channel subfamily H member 2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CaV3 (Caveolin-3)KCNK10

Beyond the preview

Go deeper on verapamil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on verapamil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call